⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MNOV News
Medicinova, Inc.
MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment
globenewswire.com
MNOV
MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
globenewswire.com
MNOV
MN-166 Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan
globenewswire.com
MNOV
New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
globenewswire.com
MNOV
MediciNova to Participate at the 38th Annual ROTH Conference
globenewswire.com
MNOV
Form 8-K
sec.gov
MNOV
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
globenewswire.com
MNOV
2026 New Year’s Greetings from the CEO
globenewswire.com
MNOV
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
globenewswire.com
MNOV
Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throughout Forecast Period (2025-2034) | DelveInsight
prnewswire.com
NRSN
IONQ
MNOV
CLNN
RVSN
BIIB
ABSI
CLNE